Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated yesterdaySource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 16, 2022 | Capmatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TABRECTA (DIN 02527391) under ATC L01EP01 CAPMATINIB. Indications are not published in the Drug Product Database —… | DIN02527391 | approvedsource: Marketed | health-canada-dpd |
| Sep 15, 2022 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02517647) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02517647 | approvedsource: Marketed | health-canada-dpd |
| Sep 15, 2022 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02517639) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02517639 | approvedsource: Marketed | health-canada-dpd |
| Sep 14, 2022 | Chlormethine | Health Canada CA | cancer not stated in this record | Marketed in Canada as LEDAGA (DIN 02516764) under ATC L01AA05 CHLORMETHINE. Indications are not published in the Drug Product Database —… | DIN02516764 | approvedsource: Marketed | health-canada-dpd |
| Sep 1, 2022 | Belzutifan | Health Canada CA | cancer not stated in this record | Marketed in Canada as WELIREG (DIN 02528908) under ATC L01XX74 BELZUTIFAN. Indications are not published in the Drug Product Database — see… | DIN02528908 | approvedsource: Marketed | health-canada-dpd |
| Sep 1, 2022 | Asciminib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SCEMBLIX (DIN 02528339) under ATC L01EA06 ASCIMINIB. Indications are not published in the Drug Product Database — see… | DIN02528339 | approvedsource: Marketed | health-canada-dpd |
| Sep 1, 2022 | Asciminib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SCEMBLIX (DIN 02528320) under ATC L01EA06 ASCIMINIB. Indications are not published in the Drug Product Database — see… | DIN02528320 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2022 | Pazopanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-PAZOPANIB (DIN 02525666) under ATC L01EX03 PAZOPANIB. Indications are not published in the Drug Product Database… | DIN02525666 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 27, 2022 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516799) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02516799 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 27, 2022 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as AYBINTIO (DIN 02522837) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02522837 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 19, 2022 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02501295) under ATC L01CE02 IRINOTECAN. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 28, 2022 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as BICALUTAMIDE (DIN 02519178) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02519178 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 31, 2022 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN INJECTION, USP (DIN 02457423) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 24, 2022 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AZACITIDINE FOR INJECTION (DIN 02507668) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 31, 2022 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION SDZ (DIN 02503352) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 29, 2022 | Tretinoin | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP TRETINOIN (DIN 02520036) under ATC L01XF01 TRETINOIN. Indications are not published in the Drug Product Database… | DIN02520036 | approvedsource: Marketed | health-canada-dpd |
| Aug 25, 2022 | Fludarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUDARABINE PHOSPHATE INJECTION, USP (DIN 02438577) under ATC L01BB05 FLUDARABINE. Indications are not published in… | DIN02438577 | approvedsource: Marketed | health-canada-dpd |
| Aug 23, 2022 | Tebentafusp | Health Canada CA | cancer not stated in this record | Marketed in Canada as KIMMTRAK (DIN 02527588) under ATC L01XX75 TEBENTAFUSP. Indications are not published in the Drug Product Database —… | DIN02527588 | approvedsource: Marketed | health-canada-dpd |
| Aug 5, 2022 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516802) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02516802 | approvedsource: Marketed | health-canada-dpd |
| Aug 1, 2022 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as AZACITIDINE FOR INJECTION (DIN 02501791) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN02501791 | withdrawnsource: Dormantsince Jul 31, 2025 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 26, 2022 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516845) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02516845 | approvedsource: Marketed | health-canada-dpd |
| Jul 26, 2022 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516829) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02516829 | approvedsource: Marketed | health-canada-dpd |
| Jul 25, 2022 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516810) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02516810 | approvedsource: Marketed | health-canada-dpd |
| Jul 20, 2022 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONTRUZANT (DIN 02524325) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02524325 | approvedsource: Marketed | health-canada-dpd |
| Jul 20, 2022 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONTRUZANT (DIN 02524317) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02524317 | approvedsource: Marketed | health-canada-dpd |
| Jul 18, 2022 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as LETROZOLE (DIN 02524244) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02524244 | approvedsource: Marketed | health-canada-dpd |
| Jul 18, 2022 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-BORTEZOMIB (DIN 02511932) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product… | DIN02511932 | approvedsource: Marketed | health-canada-dpd |
| Jul 13, 2022 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN INJECTION, USP (DIN 02458403) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug… | DIN02458403 | approvedsource: Marketed | health-canada-dpd |
| Jul 12, 2022 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as ABIRATERONE (DIN 02525380) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product Database… | DIN02525380 | withdrawnsource: Dormantsince Jul 31, 2025 | health-canada-dpd |
| Jul 7, 2022 | Selinexor | Health Canada CA | cancer not stated in this record | Marketed in Canada as XPOVIO (DIN 02527677) under ATC L01XX66 SELINEXOR. Indications are not published in the Drug Product Database — see… | DIN02527677 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jun 27, 2022 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as AYBINTIO (DIN 02522829) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02522829 | approvedsource: Marketed | health-canada-dpd |
| Jun 17, 2022 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED FOR INJECTION, USP (DIN 02463091) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug… | DIN02463091 | approvedsource: Marketed | health-canada-dpd |
| Jun 17, 2022 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED FOR INJECTION, USP (DIN 02463083) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug… | DIN02463083 | approvedsource: Marketed | health-canada-dpd |
| Jun 16, 2022 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPECITABINE (DIN 02519887) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02519887 | approvedsource: Marketed | health-canada-dpd |
| Jun 15, 2022 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPECITABINE (DIN 02519879) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02519879 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| May 19, 2022 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02501279) under ATC L01CE02 IRINOTECAN. Indications are not published in the… | DIN02501279 | approvedsource: Marketed | health-canada-dpd |
| May 10, 2022 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED FOR INJECTION (DIN 02515423) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug… | DIN02515423 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 26, 2022 | Amivantamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as RYBREVANT (DIN 02526182) under ATC L01FX18 AMIVANTAMAB. Indications are not published in the Drug Product Database —… | DIN02526182 | approvedsource: Marketed | health-canada-dpd |
| Apr 21, 2022 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTARABINE INJECTION (DIN 02515296) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product… | DIN02515296 | approvedsource: Marketed | health-canada-dpd |
| Apr 13, 2022 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ABEVMY (DIN 02522179) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see… | DIN02522179 | approvedsource: Marketed | health-canada-dpd |
| Apr 13, 2022 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ABEVMY (DIN 02522160) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see… | DIN02522160 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Mar 28, 2022 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ ABIRATERONE (DIN 02521644) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02521644 | approvedsource: Marketed | health-canada-dpd |
| Mar 25, 2022 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as NRA-LETROZOLE (DIN 02520486) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02520486 | approvedsource: Marketed | health-canada-dpd |
| Mar 11, 2022 | Arsenic Trioxide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ARSENIC TRIOXIDE FOR INJECTION (DIN 02513420) under ATC L01XX27 ARSENIC TRIOXIDE. Indications are not published in… | DIN02513420 | approvedsource: Marketed | health-canada-dpd |
| Mar 2, 2022 | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as FULVESTRANT INJECTION (DIN 02486792) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug Product… | DIN02486792 | withdrawnsource: Cancelled Post Marketsince Nov 1, 2024 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 22, 2022 | Dostarlimab | Health Canada CA | cancer not stated in this record | Marketed in Canada as JEMPERLI (DIN 02523434) under ATC L01FF07 DOSTARLIMAB. Indications are not published in the Drug Product Database —… | DIN02523434 | approvedsource: Marketed | health-canada-dpd |
| Feb 3, 2022 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as AG-LETROZOLE (DIN 02374439) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02374439 | withdrawnsource: Dormantsince Aug 3, 2026 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 31, 2026 |
| health-canada-dpd |
| Jan 21, 2022 | Selpercatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as RETEVMO (DIN 02516926) under ATC L01EX22 SELPERCATINIB. Indications are not published in the Drug Product Database —… | DIN02516926 | approvedsource: Marketed | health-canada-dpd |
| Jan 21, 2022 | Selpercatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as RETEVMO (DIN 02516918) under ATC L01EX22 SELPERCATINIB. Indications are not published in the Drug Product Database —… | DIN02516918 | approvedsource: Marketed | health-canada-dpd |
| Jan 6, 2022 | Pemigatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMAZYRE (DIN 02519933) under ATC L01EN02 PEMIGATINIB. Indications are not published in the Drug Product Database —… | DIN02519933 | approvedsource: Marketed | health-canada-dpd |